Next Article in Journal
Injectable Synthetic Beta-Tricalcium Phosphate/Calcium Sulfate (GeneX) for the Management of Contained Defects Following Curettage of Benign Bone Tumours
Next Article in Special Issue
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
Previous Article in Journal
Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
Previous Article in Special Issue
Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)
 
 
Review

Article Versions Notes

Curr. Oncol. 2023, 30(4), 3684-3696; https://doi.org/10.3390/curroncol30040280
Action Date Notes Link
article xml file uploaded 27 March 2023 05:58 CEST Original file -
article xml uploaded. 27 March 2023 05:58 CEST Update https://www.mdpi.com/1718-7729/30/4/280/xml
article pdf uploaded. 27 March 2023 05:58 CEST Version of Record https://www.mdpi.com/1718-7729/30/4/280/pdf
article html file updated 27 March 2023 05:59 CEST Original file -
article html file updated 6 April 2023 22:45 CEST Update https://www.mdpi.com/1718-7729/30/4/280/html
Back to TopTop